PDLI earnings call for the period ending March 31, 2019.
News & Analysis: PDL BioPharma
Investors are cheering an incredible profit improvement announced Thursday afternoon. But there's a good reason they aren't cheering more loudly.
A convertible offering causes investors to hit the brakes.
A dilutive capital raise and a late-stage trial failure at Eli Lilly are weighing down shares.
The free money train has ended for PDL BioPharma shareholders.
Investors march out of PDL BioPharma after the company eliminates its dividend program.
The "Queen" has fallen, and so has PDL BioPharma's dividend.
The "Queen" has fallen, and so with it have PDL's profits and dividend.
Higher than expected fourth-quarter profits has investors seeing green today.